Table 1.
Comparison of baseline characteristics for selected COPD patients with increased peripheral blood eosinophils. GOLD = Global Initiative for Chronic Obstructive Lung Disease; Eos = eosinophils; Mepo = mepolizumab; Benra = benralizumab; BD = bronchodilator; ICS = inhaled corticosteroids; LABA = long-acting beta 2 agonist; LAMA = long-acting muscarinic antagonist. References: 1. Pavord ID, et al. N Engl J Med. 2017; 377:1613–1629. 2. Brightling CE, et al. Lancet Respir Med. 2014; 2:891–901. 3. Criner GJ, et al. N Engl J Med. 2019; 381:1023–1034.
| Study |
METREX1 |
METREO1 |
Brightling et al.2 |
GALATHEA3 |
TERRANOVA3 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inclusion criteria for eosinophils | Peripheral blood Eos ≥ 150/μL at screening or ≥300/μL during the previous year |
Sputum Eos ≥3% |
Peripheral blood Eos ≥ 220/μL at baseline |
|||||||||||
| Mepo 100 mg |
Placebo | Mepo 100 mg |
Mepo 300 mg |
Placebo | Benra 100 mg |
Placebo | Benra 30 mg |
Benra 100 mg |
Placebo | Benra 10 mg |
Benra 30 mg |
Benra 100 mg |
Placebo | |
| n | 233 | 229 | 223 | 225 | 226 | 51 | 50 | 382 | 379 | 359 | 377 | 394 | 386 | 388 |
| Age | 65 ± 8 | 65 ± 9 | 65 ± 9 | 65 ± 9 | 66 ± 9 | 63 ± 8 | 65 ± 8 | 66 ± 8 | 66 ± 8 | 66 ± 8 | 65 ± 8 | 66 ± 8 | 65 ± 8 | 65 ± 8 |
| Female (%) | 36 | 34 | 41 | 30 | 31 | 31 | 42 | 29 | 31 | 28 | 33 | 32 | 35 | 35 |
| Current smoker (%) | 27 | 31 | 25 | 32 | 28 | 33 | 42 | 37 | 34 | 32 | 29 | 27 | 28 | 30 |
| Ex-smoker (%) | 70 | 64 | 73 | 66 | 71 | 67 | 58 | 63 | 66 | 68 | 71 | 73 | 72 | 70 |
| GOLD group D (%) | 94 | 95 | 95 | 97 | 96 | – | – | – | – | – | – | – | – | – |
| Exacerbations in the previous year | 2.6 ± 1.3 | 2.5 ± 1.2 | 2.5 ± 1.2 | 2.7 ± 1.4 | 2.7 ± 1.5 | 1.6 ± 1.0 | 1.6 ± 1.0 | 2.3 ± 1.2 | 2.3 ± 1.2 | 2.4 ± 1.4 | 2.3 ± 1.0 | 2.2 ± 1.0 | 2.3 ± 1.0 | 2.3 ± 1.0 |
| Post-BD % predicted FEV1 | 45 ± 15 | 43 ± 15 | 47 ± 15 | 45 ± 16 | 46 ± 15 | 44 ± 16 | 50 ± 18 | 42 ± 11 | 44 ± 12 | 43 ± 13 | 44 ± 12 | 43 ± 12 | 43 ± 12 | 43 ± 11 |
| Geometric mean Eos (/mm3) | 260 | 290 | 300 | 310 | 310 | – | – | – | – | – | – | – | – | – |
| Baseline mean Eos (/mm3) | – | – | – | – | – | 249 ± 193 | 230 ± 165 | 451 ± 281 | 459 ± 277 | 450 ± 283 | 518 ± 420 | 503 ± 389 | 504 ± 404 | 493 ± 360 |
| ICS/LABA/LAMA (%) | 100 | 50 | 41 | 72.3 | 69.1 | 67.4 | 57.3 | 56.9 | 61.4 | 59.0 | ||||
| ICS/LABA (%) | – | 10 | 10 | 18.8 | 21.1 | 24.0 | 34.7 | 32.3 | 34.5 | 34.3 | ||||
| LABA/LAMA (%) | – | – | 8.6 | 9.8 | 8.6 | 7.7 | 10.7 | 4.1 | 6.4 | |||||
| Current asthma (%) | excluded | excluded | 4.5 | 6.9 | 5.0 | 1.6 | 4.3 | 3.1 | 4.1 | |||||
| Previous history of asthma (%) | excluded for never smokers with a history of asthma | – | 6.8 | 10.0 | 8.1 | 4.8 | 5.3 | 7.3 | 7.2 | |||||